SCHEMBL6922981

SCHEMBL6922981

COC(C)c1nc2cc(-c3cccc(F)c3)ccc2c(=O)n1C

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TNKS2 Q9H2K2 1/20 0.40
CYP3A4 P08684 5/20 0.39
CYP1A2 P05177 3/20 0.39
ALDH1A1 P00352 2/20 0.39
CLK4 Q9HAZ1 2/20 0.39
USP2 O75604 2/20 0.39
TSHR P16473 2/20 0.39
TGFBR1 P36897 1/20 0.39
PDGFRB P09619 1/20 0.39
PDGFRA P16234 1/20 0.39
BACE1 P56817 1/20 0.38
PGR P06401 1/20 0.37
CYP2C19 P33261 2/20 0.37
GLA P06280 1/20 0.37
HSD17B10 Q99714 1/20 0.37
KDM5B Q9UGL1 1/20 0.36
GRIN1 Q05586 1/20 0.36
GRIN2B Q13224 1/20 0.36
MAOA P21397 1/20 0.35
MAOB P27338 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12059499 0.84 TGFBR1 (0.42) TNKS2CYP3A4CYP1A2ALDH1A1CLK4
SCHEMBL2053582 0.84 GRM5 (0.40)
SCHEMBL6921132 0.79 CYP3A4 (0.46) CYP3A4TGFBR1
SCHEMBL6923028 0.78 PARG (0.42) TNKS2CYP3A4CYP1A2ALDH1A1CLK4
SCHEMBL12059535 0.78 CYP3A4 (0.41) TNKS2CYP3A4CYP1A2ALDH1A1CLK4
SCHEMBL6922234 0.77 CACNA2D1 (0.40) CYP3A4ALDH1A1USP2
SCHEMBL6921853 0.76 CYP3A4 (0.45) TNKS2CYP3A4CYP1A2ALDH1A1CLK4
SCHEMBL12059534 0.74 PIM1 (0.44) TNKS2CYP3A4CYP1A2ALDH1A1CLK4
SCHEMBL1463643 0.72 KCNH2 (0.52) CYP3A4CYP1A2ALDH1A1USP2TSHR
SCHEMBL12059512 0.72 BCL2A1 (0.42) TNKS2CYP3A4CYP1A2ALDH1A1CLK4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110319380-A1 Compounds for Treating Disorders Mediated by Metabotropic Glutamate Receptor 5, and Methods of Use Thereof SUNOVION PHARMACEUTICALS INC. (US) 2011-12-29 US disclosed
WO-2011075699-A2 COMPOUNDS FOR TREATING DISORDERS MEDIATED BY METABOTROPIC GLUTAMATE RECEPTOR 5, AND METHODS OF USE THEREOF SUNOVION PHARMACEUTICALS INC. (US) 2011-06-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110319380-A1 Compounds for Treating Disorders Mediated by Metabotropic Glutamate Receptor 5, and Methods of Use Thereof GRM5, GRM2, GRM1 TNKS2 3475/4885CYP3A4 4447/4885CYP1A2 4540/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.